Nothing Special   »   [go: up one dir, main page]

Saba et al., 1968 - Google Patents

Anti-heparin activity of lysosomal cationic proteins from polymorphonuclear leukocytes

Saba et al., 1968

Document ID
1619897984204492162
Author
Saba H
Roberts H
Herion J
Publication year
Publication venue
Blood

External Links

Snippet

The lysosomal cationic proteins (LCP) of rabbit polymorphonuclear leukocytes have previously been shown to inhibit the formation of intrinsic prothrombin activator. That they also have anti-heparin activity is now demonstrated in a thrombin-plasma clotting system …
Continue reading at ashpublications.org (other versions)

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/81—Protease inhibitors
    • G01N2333/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • G01N2333/811—Serine protease (E.C. 3.4.21) inhibitors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)

Similar Documents

Publication Publication Date Title
Colucci et al. Generation in plasma of a fast-acting inhibitor of plasminogen activator in response to endotoxin stimulation.
Saba et al. Anti-heparin activity of lysosomal cationic proteins from polymorphonuclear leukocytes
Aberg et al. Effect of dextran on factor VIII (antihemophilic factor) and platelet function.
US6566140B2 (en) Inhibition of coagulation in blood and blood products
Harris et al. Collagenases in human synovial fluid
Niemetz Coagulant activity of leukocytes. Tissue factor activity
Fletcher et al. Pathogenesis of the coagulation defect developing during pathological plasma proteolytic (“fibrinolytic”) states. I. The significance of fibrinogen proteolysis and circulating fibrinogen breakdown products
Page et al. The cause of the blood coagulation defect following abruptio placentae
Contant et al. Heparin inactivation during blood storage: its prevention by blood collection in citric acid, theophylline, adenosine, dipyridamole-CTAD mixture
Bellucci et al. Platelet hyperactivation in patients with essential thrombocythemia is not associated with vascular endothelial cell damage as judged by the level of plasma thrombomodulin, protein S, PAI-1, t-PA and vWF
Lu et al. Temperature dependence of plasmin-induced activation or inhibition of human platelets
Lipscomb et al. Human platelets and factor XI: Localization in platelet membranes of factor XI-like activity and its functional distinction from plasma factor XI
Kirchhof et al. The determination of prothrombin using synthetic chromogenic substrates; choice of a suitable activator
Saba et al. The anticoagulant activity of lysosomal cationic proteins from polymorphonuclear leukocytes
Liebman et al. Depression of functional and antigenic plasma antithrombin III (AT‐III) due to therapy with L‐asparaginase
Schipper et al. Antithrombin III deficiency in surgical intensive care patients
Canoso et al. A chlorpromazine‐induced inhibitor of blood coagulation
Janoff et al. Inhibition of the elastase-like esterase in human leukocyte granules by human leukocyte cell sap
Abildgaard Antithrombin–early prophecies and present challenges
Poon et al. Evidence that functional subunits of antihemophilic factor (Factor VIII) are linked by noncovalent bonds
Zammit et al. Interaction of immobilised unfractionated and LMW heparins with proteins in whole human plasma
Lalloo et al. Coagulopathy following bites by the Papuan taipan (Oxyuranus scutellatus canni)
van de Putte et al. Activators and inhibitors of fibrinolysis in rheumatoid and nonrheumatoid synovial membranes
Wessler et al. On the antithrombotic action of heparin
Kondo et al. Cold Activation of Complement: I. Presence of Coagulation-Related Activator